Objective: This study aimed to explore and analyze the therapeutic effect of the combination of Bifidobacterium animalis subsp. lactis BB-12® and Lactobacillus rhamnosus GG on underweight and malabsorption in premature infants.
Methods: This is a retrospective study. The clinical data of 68 premature infants admitted to Beijing United Family Hospital (Private Secondary Comprehensive Hospital, Chaoyang District, Beijing, China) from January 2016 to January 2022 were analyzed retrospectively. Preterm infants less than 37 weeks of gestational age admitted to the neonatal intensive care unit were included in the study. Patients with intestinal malformations, necrotizing enterocolitis, etc., who require long-term fasting were excluded. A telephone follow-up was performed 3-6 months after discharge. They were classified as treatment groups A and B according to the treatment plan. The treatment group A included parenteral nutrition, enteral nutrition, etc. In treatment group B, based on treatment group A, the premature infants were treated with Bifidobacterium animalis subsp. lactis BB-12® and Lactobacillus rhamnosus GG. The time to regain birthweight and the weight on day 30 were compared between the two groups, as was the duration of transition from parenteral nutrition to total enteral nutrition.
Results: The time of weight regain birthweight in group B was shorter than that in group A (t=-2.560; t=-4.287; p<0.05). The increase of weight on day 30 in group B was significantly higher than that in group A (t=2.591; t=2.651; p<0.05). The time from parenteral nutrition to total enteral nutrition in group B was shorter than that in group A (z=-2.145; z=-2.236; p<0.05).
Conclusion: In the treatment of premature infants, the combination of Bifidobacterium animalis subsp. lactis BB-12® and Lactobacillus rhamnosus GG can have a better therapeutic effect on the underweight and malabsorption of premature infants, and this treatment method can be popularized in clinics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10890203 | PMC |
| http://dx.doi.org/10.1590/1806-9282.20230636 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preparation of a potentially synbiotic dairy product fortified with galactooligosaccharides.
J Dairy Res
March 2025
Department of Dairy, Fat and Cosmetics, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague, Czech Republic.
We assessed the chemical, microbiological, rheological and sensory parameters of a fermented dairy product (FDP) containing a galactooligosaccharide (GOS) preparation. This was made from a solution of dried whey and skim milk containing 25% (w/w) lactose using a new enzyme with high transgalactosylation activity (Nurica: Danisco A/S). Conversion of the high initial lactose content enabled a good yield of 56% GOS to be achieved.
View Article and Find Full Text PDFEffects of a Novel Fortified Dairy Product on the Psychological Status and Sleep Quality of Patients with Polycystic Ovary Syndrome: A Double-Blind Randomized Controlled Trial.
Prev Nutr Food Sci
February 2025
Dairy Expert at Research and Development of Zarrin Ghazal Company (DAITY), Shiraz 7158188785, Iran.
Polycystic ovary syndrome (PCOS) is a neuroendocrine disorder that commonly causes anovulation and infertility worldwide. Aside from infertility, patients with PCOS suffer from sleep disturbances and mental health issues. Recent studies have shown that functional foods may have a beneficial impact on psychological disorders and sleep quality.
View Article and Find Full Text PDFPreparation, characterization, antioxidant activity and intestinal bacteria activity verification of Xylooligosaccharides from Pueraria lobata straw.
J Food Sci
March 2025
School of Environmental and Quality Testing, Chongqing Chemical Industry Vocational College, Chongqing, China.
To promote the comprehensive utilization of Pueraria lobata (P. lobata) straw, this study explored the antioxidant activity and probiotic activity of its xylooligosaccharides (XOS). The hemicellulose B from P.
View Article and Find Full Text PDFSupplementation with the Postbiotic BPL1™-HT (Heat-Inactivated subsp. Lactis) Attenuates the Cardiovascular Alterations Induced by Angiotensin II Infusion in Mice.
Antioxidants (Basel)
February 2025
Departamento de Fisiología, Facultad de Medicina, Universidad Autónoma de Madrid, 28029 Madrid, Spain.
Hypertension is associated with alterations in the composition and diversity of the intestinal microbiota. Indeed, supplementation with probiotics and prebiotics has shown promising results in modulating the gut microbiota and improving cardiovascular health. However, there are no studies regarding the possible beneficial effects of postbiotics on cardiovascular function and particularly on hypertension-induced cardiovascular alterations.
View Article and Find Full Text PDFBifidobacterium animalis subsp. lactis A6 ameliorates bone and muscle loss via modulating gut microbiota composition and enhancing butyrate production.
Bone Res
February 2025
Senior Department of Orthopedics, The Fourth Medical Center of Chinese PLA General Hospital, Beijing, China.
Systematic bone and muscle loss is a complex metabolic disease, which is frequently linked to gut dysfunction, yet its etiology and treatment remain elusive. While probiotics show promise in managing diseases through microbiome modulation, their therapeutic impact on gut dysfunction-induced bone and muscle loss remains to be elucidated. Employing dextran sulfate sodium (DSS)-induced gut dysfunction model and wide-spectrum antibiotics (ABX)-treated mice model, our study revealed that gut dysfunction instigates muscle and bone loss, accompanied by microbial imbalances.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!